Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-FAP antibody-drug conjugate OMTX705

An antibody-drug conjugate (ADC) composed of OMTX005, a humanized monoclonal antibody directed against fibroblast activation protein (FAP), conjugated to the cytotoxic tubulysin TAM470, with potential antineoplastic activity. Upon administration of anti-FAP ADC OMTX705, the anti-FAP monoclonal antibody moiety targets and binds to FAP expressed on cancer-associated fibroblasts (CAFs) in the tumor stroma. Upon binding, internalization and linker cleavage, the cytotoxic moiety is released, which binds to tubulin and inhibits microtubule polymerization. This results in G2/M phase arrest and the apoptosis of FAP-expressing CAFs. FAP, a membrane-bound serine protease overexpressed on CAFs, is minimally expressed on normal, healthy cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-FAP ADC OMTX705
Code name:OMTX 705
OMTX-705
OMTX705
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search